The agreement gives Lilly exclusive rights to Ascidian's RNA exon-editing technology, which repairs faulty genes without altering a patient's DNA 0 0 MAXIMUS Infomundi's AI Listen Turning complex stories into clear, actionable insights. Complete the captcha to unlock Maximus Chat with Maximus Ask anything about this story
Eli Lilly is striking a $1.9 billion gene-editing deal to develop inherited kidney disease treatments
The agreement gives Lilly exclusive rights to Ascidian's RNA exon-editing technology, which repairs faulty genes without altering a patient's DNA
Turning complex stories into clear, actionable insights.
Complete the captcha to unlock Maximus
Share this article:
Quartz
Brought to you by InfomundiLike this publisher? Add them to your personal feed and combine publishers, tags, and categories to build a custom news page just for you.
Related coverage
Tags
Ascidian RNA billion gene-editing Eli Lilly patient DNA RNA exon-editingGlobal Coverage
This story is being covered by 0 countries
Trending